Molecular and Cellular Biology Core
Molecular and Cellular Biology Core
批准号:
10642676
负责人:
Philip Ross Hardwidge
金额:
$34.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-01 至 2025-04-30
关键词:
Advisory CommitteesAnimal ModelAreaBiochemicalBiochemistryBioinformaticsBiological AssayBiologyBiomedical ResearchBiophysicsCRISPR/Cas technologyCell SeparationCenters of Research ExcellenceClustered Regularly Interspaced Short Palindromic RepeatsCollectionCommittee MembersCommunicable DiseasesCommunicationCommunitiesCore FacilityDNA sequencingDataData SetDiagnosticDoctor of PhilosophyElectron MicroscopyEmployeeEnvironmentEquipmentExtramural ActivitiesFacultyFinancial SupportFlow CytometryFluorescence MicroscopyFundingGoalsGrowthImage CytometryImaging technologyIndividualInfrastructureKansasLaboratoriesLeadershipMaintenanceMentorsMethodologyModernizationMolecularMolecular and Cellular BiologyPathogenesisPathologyPerformancePostdoctoral FellowResearchResearch PersonnelResearch Project GrantsResourcesServicesTeacher Professional DevelopmentTechniquesTechnologyTimeTrainingUniversitiesVeterinary MedicineZoonosescollegeequipment acquisitionexperienceexperimental studygraduate studentimprovedinnovationinstrumentlaser capture microdissectionmembernext generationpathogenprogramssingle-cell RNA sequencingsynergismundergraduate studentvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary:
The Molecular and Cellular Biology (MCB) Core facility will be modernized and enhanced by adding new
equipment and services to expand the capabilities of the facility. The MCB Core is a fully functional research
core that currently provides imaging and flow cytometry services to CVM users. MCB Core facility improvements
will focus on expanding the DNA sequencing, CRISPR technology, and cell sorting capabilities. Significant new
financial support from Kansas State University (KSU) for new equipment acquisition and facility maintenance
and sustainability has been obtained and will further expand the range of technologies available in the facility,
providing cutting-edge technological support for current and future research projects. Dr. Philip R. Hardwidge, a
bacterial pathogenesis expert, will serve as MCB Core director. Dr. Waithaka Mwangi, the current director of
KSU CVM's flow cytometry facility and a vaccine development expert, will serve as MCB Core associate director,
providing additional senior leadership. MCB Core support for bioinformatics and handling of large DNA
sequencing datasets will be provided by the KSU Bioinformatics Center, under the direction of Dr. Sue Brown,
Division of Biology. Expert technical support for DNA sequencing will be provided by Dr. Doug Marthaler, the
current director of DNA sequencing in the KSU Veterinary Diagnostic Laboratory. Implementation and refinement
of cutting-edge CRISPR technology will be provided by Dr. Greg Finnigan, in the KSU Biochemistry and
Molecular Biophysics Department. Additional technological, project-specific advice and mentoring will be
provided by the COBRE mentoring team, internal and external advisory committee members, and members from
the CVM and Division of Biology at KSU. A senior research associate, Mike Hays, will provide day-to-day
management of the facility, and will communicate with project leaders to identify specific, evolving needs for
individual projects and the Core. Mike Hays possesses significant experience in the molecular and cellular
biology methodologies that will be utilized. The Core has already established the feasibility of providing advanced
imaging technology, next-generation DNA sequencing and CRISPR resources to junior project leaders. These
activities will be tightly integrated with the Animal Model and Pathology (AMP) Core. The AMP core will also
undergo technological upgrades, including the acquisition of a laser capture microdissection instrument.
Significant synergy will exist between the two cores and will allow for the first time at KSU the performance of
single-cell RNA-Seq experiments. The MCB Core will directly support the Center's primary and pilot/seed
projects, as well as the community of users within KSU and the regional scientific network (RSN), including
faculty, staff, postdocs, and graduate students. The significant enhancement of the MCB Core facilities will also
provide an excellent training environment for the robust Ph.D. program at KSU. Most importantly, MCB Core
upgrades will improve the overall infrastructure for biomedical research at KSU.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T3SS Effector Regulation of Bacterial Metabolism
-
批准号:10425770
-
项目类别:
-
资助金额:$18.65万
-
财政年份:2022
-
负责人:Philip Ross Hardwidge
-
依托单位:
Molecular and Cellular Biology Core
-
批准号:10397674
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2020
-
负责人:Philip Ross Hardwidge
-
依托单位:
Functions of Translocated Bacterial Glycosyltransferases
-
批准号:9222103
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2016
-
负责人:Philip Ross Hardwidge
-
依托单位:
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway
-
批准号:8891351
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8791592
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:9188797
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8495491
-
项目类别:
-
资助金额:$8.81万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Reverse vaccinology of enterotoxigenic E. coli
-
批准号:8518225
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2012
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8589734
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2012
-
负责人:Philip Ross Hardwidge
-
依托单位:
Reverse vaccinology of enterotoxigenic E. coli
-
批准号:8589931
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2012
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8296462
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8227954
-
项目类别:
-
资助金额:$2.9万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8184998
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8609163
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8636895
-
项目类别:
-
资助金额:$6.67万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8088850
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector subversion of host protein trafficking
-
批准号:7862895
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
Disruption of NF-kB signaling by diarrheagenic Escherichia coli
-
批准号:8129920
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector subversion of host protein trafficking
-
批准号:8019137
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
MODULATION OF NF-KB SIGNALLING BY E COLI PROTEIN KINASES
-
批准号:8168402
-
项目类别:
-
资助金额:$26.93万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
海外基金